First Targeted Treatment for Kidney Disease?
(Ivanhoe Newswire) –A drug originally approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost always leads to kidney failure.
Researchers at Massachusetts General Hospital have found that treatment with abatacept (Orencia) appeared to halt the course of focal segmental glomerulosclerosis (FSGS) in five patients, preventing four from losing transplanted kidneys and achieving disease remission in the fifth.
"We identified abatacept as the first personalized, targeted treatment for kidney disease and specifically for FSGS, a devastating and largely untreatable disease. We also identified a biomarker that helps us discern which patients are most likely to benefit from therapy with abatacept,” Peter Mundel, MD, of the Division of Nephrology in the MGH Department of Medicine, senior author, was quoted as saying.
For more information, go to: http://www.massgeneral.org/about/pressrelease.aspx?id=1640
SOURCE: New England Journal of Medicine, November 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.